Stockreport

ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccinesrNAPc2 is the only novel compound bein [Read more]